MBD2 and prostate carcinoma: As in prostate cancer the two families of KDMs, LSD1 and JmjC enzymes (specifically, KDM4A/C), are co-expressed and colocalized with the androgen receptor, the design and synthesis of pan-demethylase inhibitors, able to hit at the same time both the families of demethylases, has a strong rationale for treatment of prostate cancer.